1 Excess weight mediates changes in HDL pool that reduce cholesterol efflux capacity 2 and increase antioxidant activity 3 Jose Carlos de Lima-Junior¹, Vitor W.M. Virginio¹, Filipe A. Moura^{1,2}, Adriana Bertolami³, Marcelo Bertolami³, Otavio R Coelho-Filho⁴, Ilaria Zanotti⁶, Wilson Nadruz⁴, Eliana Cotta 4 de Faria⁵, Luiz Sergio F. de Carvalho^{1,4}, Andrei C Sposito^{1,4} 5 6 1. Laboratory of Atherosclerosis and Vascular Biology, Faculty of Medical Sciences, State 7 University of Campinas, São Paulo, Brazil 8 2. Department of Cardiology, Brigham and Women's Hospital, Boston, New England, 9 **United States** 10 3. Department of Dyslipidemia, Dante Pazzanese Cardiological Institute, São Paulo, Brazil 11 4. Department of Internal Medicine, Cardiology Division, Faculty of Medical Sciences, 12 State University of Campinas, São Paulo, Brazil 13 5. Lipids Laboratory, Department of Clinical Pathology, Faculty of Medical Sciences, 14 State University of Campinas, Sao Paulo, Brazil 15 6. Department of Food and Drug, University of Parma, Parma, Italy 16 To whom correspondence should be addressed. E-mail: andreisposito@gmail.com 17 Corresponding author: 18 Andrei C Sposito 19 Cardiology Division, State University of Campinas 20 13084-971, Campinas, São Paulo, Brazil 21 andreisposito@gmail.com 22 Running title: Excess weight and HDL functions 23 The authors declare no conflict of interest. 24 **Keywords** - atherosclerosis; cholesterol efflux; HDL metabolism; HDL; obesity 25 26 27

Abbreviations: ALT, alanine aminotransferase; ApoA-I, apolipoprotein A-I; AST, aspartate aminotransferase; CE, cholesteryl ester; CEC, Cholesterol efflux capacity; CETP, cholesteryl ester transfer protein; cIMT, carotid intima-media thickness; FC, free cholesterol; HL, hepatic lipase; HOMA2 % β, Homeostasis model assessment 2 of beta-cell function; HOMA2-IR, Homeostasis model assessment 2 of insulin resistance; HOMA2 %S, Homeostasis model assessment 2 of insulin sensitivity; HUVEC, human umbilical vein endothelial cells; LCAT, Lecithin-cholesterol acyltransferase activity; PL, phospholipidis; LPL, Lipoprotein lipase; PON, paraoxonase; TC, total cholesterol; PLTP, phospholipids transfer protein; VCAM-1, vascular cell adhesion molecule-1.

52

53

54

55

56

57

58

59

60

61

62

63

64

65

66

67

68

69

70

71

72

73

74

75

76

77

Abstract: Objective: Obesity-related decline in high-density lipoprotein (HDL) functions such as cholesterol efflux capacity (CEC) has supported the notion that this lipoprotein dysfunction may contribute for atherogenesis among obese patients. Besides, potentially other HDL protective actions may be affected with weight gain and these changes may occur even before the obesity range. Methods: Lipid profile, body mass index (BMI), biochemical measurements, and carotid intima-media thickness (cIMT) were obtained in this cross-sectional study with 899 asymptomatic individuals. HDL functions were measured in a subgroup (n=101). Results: Individuals with increased HDL-C had an attenuated increase in cIMT with elevation of BMI. CEC, HDL-C, HDL size and HDL-antioxidant activity were negatively associated with cIMT. BMI was inversely associated with HDL-mediated inhibition of platelet aggregation and CEC, but surprisingly it was directly associated with the antioxidant activity. Thus, even in non-obese, non-diabetic individuals, increased BMI is associated with a wide change in protective functions of HDL, reducing CEC and increasing antioxidant activity. In these subjects, decreased HDL concentration, size or function are related to increased atherosclerotic burden. Conclusion: Our findings demonstrate that in non-obese, non-diabetic individuals, the increasing values of BMI are associated with impaired protective functions of HDL and concomitant increase in atherosclerotic burden.

1. Introduction

Presently, one in three individuals with excess weight will die from cardiovascular disease (CVD)[1, 2]. In fact, both obesity (BMI >30 kg/m²) and overweight (BMI of 25 to <30 kg/m²) individuals are at increased risk of cardiovascular death as compared with those with BMI within the normal range (18.5 to <25 kg/m²)[3]. The proposed milieu for this interaction involves a spectrum of mechanisms in which phenotypic or functional changes in high-density lipoprotein (HDL) are involved [4].

The identification of HDL involvement in adiposopathy is not a recent issue. Since the metabolic syndrome was conceived, all clinical criteria for its diagnosis included low levels of plasma HDL-cholesterol (HDL-C) as a marker of metabolically, unhealthy obesity. In the mechanistic point of view, the combination of increased substrate, such as triglyceride-rich lipoproteins, and increased activity of HDL remodeling proteins, such as cholesteryl ester transfer protein (CETP), and hepatic lipase (HL), coexists in overweight individuals as a result of insulin resistance, promoting a reduction in HDL concentration, size and its content of apolipoproteins AI (ApoA-I). In addition, a decrease in the overall cholesterol efflux capacity (CEC) has been reported in obese subjects [5], despite the increased ABCA1-mediated cholesterol efflux[6].

Besides CEC, HDL also mediates several other anti-atherosclerotic mechanisms, such as antioxidant, anti-inflammatory activities and inhibition of platelet aggregation, whose extent is sensitive to phenotypic changes of the particles, such as those described above. If this is so, more than the reduced capacity as free cholesterol acceptor, an overall dysfunction in the HDL system may follow weight gain [7]. Furthermore, as the magnitude of these phenotypic changes in HDL occurs in parallel with the increase in BMI, it is possible that a cluster of particle dysfunctions occurs earlier with the weight gain, possibly even before the criterion for overweight. Hence, a metabolic legacy related to HDL may contribute to the future CVD risk. In order to shed some light on these gaps, we designed this study to evaluate the impact of BMI

on the interaction between HDL concentration and functions with atherosclerotic burden in preobese individuals.

We evaluated a sample of 899 asymptomatic individuals who were seen in two primary

2. Materials and methods

104

105

106

107

108

109

110

111

112

113

114

115

116

117

118

119

120

121

122

123

124

125

126

127

128

129

130

2.1. Cross-sectional study description

care centers between 2008 and 2013: the outpatient clinic at Dante Pazzanese Institute of Cardiology, São Paulo (SP), Brazil, and governmental primary care centers of the city of Campinas, SP, Brazil. Inclusion criteria were: (1) no manifested atherosclerotic CVD; (2) no diagnosis of type 2 diabetes based on antidiabetic treatment, fast blood glycemia >126 mg/dL, glycated hemoglobin ≥6.5% or glycemia ≥200 mg/dL on 120-minutes oral tolerance test and (3) age between 20 and 75 years old. We excluded individuals with (1) uncontrolled hyper (thyroid stimulating hormone (TSH) <0.41 \(\mu \text{U/mL} \) or free thyroxin >1.8 \(\text{ng/dL} \) or hypothyroidism (TSH>4.50µUI/mL or free thyroxin <0.9 ng/dL); (2) antidiabetic medications; (3) liver disease, as indicated by ALT or AST over two times the upper limit; (4) urea >40mg/dL; (5) glomerular filtration rate ≤60 mL/min/1.73m²; (6) heart failure NYHA stage ≥III; (7) HIV positive or (8) withdrawal of informed consent. Patients underwent clinical examination, as well as biochemical analysis. Subclinical atherosclerosis was measured in all patients up to a month after being included. The study was approved by the local institutional ethical committee of the Instituto Dante Pazzanese de Cardiologia (registration number 3852/2009). It is also registered at ClinicalTrials.Gov by the identification NCT02487615. All patients provided written and informed consent forms before taking part in the study. The study protocol conforms to the ethical guidelines of the 1975 Declaration of Helsinki. A sub-analysis testing functions and characteristics of HDL was performed in consecutive sample of 101 individuals from the enrolled participants in the governmental primary care centers of the city of Campinas. The study was approved by the local institutional ethical committee of the Hospital das Clínicas of the State University of Campinas (registration number 1260/2010). It is registered at ClinicalTrials.Gov by the identification NCT02106013. All patients provided written and informed consent forms before taking part in the study. The study protocol conforms to the ethical guidelines of the 1975 Declaration of Helsinki.

2.2. Biochemical analysis

Blood samples were drawn after a 12-hour fasting period. The following biochemical measurements were performed: triglycerides, total cholesterol, HDL-C, creatinine, c-reactive protein (CRP), insulin, glucose, and insulin. LDL-C was calculated using Friedewald's equation. Glomerular filtration rate was calculated by the CKD-EPI equation. HOMA2 % S, HOMA2-IR and HOMA2%β were calculated using computer models [8].

2.3. Carotid artery ultrasound

Carotid Doppler ultrasound was performed using high-resolution Vivid 7 ultrasound (GE, USA) and high-frequency linear transducer (9 MHz) with automatic border recognizer detection as described previously in Bertolami et al [9]. Briefly, the cIMT was obtained by means of image processing of B-mode ultrasonograms of the right and left automatic measurement. High-resolution B-mode ultra-sonographic imaging was performed initially evaluating the common carotid artery with antero-oblique insonation above the clavicle and alongside the internal carotid artery, as standardized procedure[10]. Measurement of cIMT was obtained 20 mm proximally from the carotid bifurcation as the distance between the lumen-intima interface and the media–adventitia interface[11].

2.4. Lipoprotein isolation

LDL was isolated from a pool of normolipidemic sera from 20 volunteers, through sequential ultracentrifugation using a Beckman L8-M ultracentrifuge (Beckman Coulter Inc., Palo Alto, USA), with a 75Ti fixed angle rotor (Havel, 1955 #11). HDL was isolated from each study participant through density gradient ultracentrifugation[12] with the use of a SW41Ti rotor. Isolated lipoproteins were extensively dialyzed against EDTA-free PBS for 24h, at 4°C, in a dark room. All assays were performed in freshly isolated lipoproteins that were kept at 4°C for a maximum period of 15 days.

2.5. HDL chemical composition and molar concentration measurements

159

160

161

162

163

164

165

166

167

168

169

170

171

172

173

174

175

176

177

178

179

180

181

182

183

184

185

HDL chemical composition was measured using commercially available enzymatic kits, in the microplate reader Power Wave XS (BioTek®, Winooski, USA). Total proteins (PierceTM BCA Protein Assay Kit, Thermo Scientific, Rockford, USA), TC (CHOD-PAP, total cholesterol, Roche Diagnostics® reagents, Mannheim, Germany), FC (Free Cholesterol E, Wako Chemicals, Richmond, USA), PL (Phospholipids C, Wako Chemicals, Richmond, USA), TG (TG, GPO-PAP, Roche Diagnostics® reagents, Mannheim, Germany) and ApoA-I (TINA OUANT APOA1 V2, Roche Diagnostics® reagents, Mannheim, Germany) were measured, while CE was calculated according to the following formula: (TC-FC) x 1.67[12]. The relative content of ApoA-I (HDL-ApoA-I) or lipids in HDL was calculated based on their proportion to the total mass of HDL, calculated as the sum of FC, PL, TG, CE, and total proteins. HDL molar concentration was estimated based on particle total mass and molecular weight[12]. 2.6. HDL physical-chemical characterization HDL particle size was determined using dynamic light scattering, in a Nanotrac Particle Size Analyser 250 (Microtrac Inc., Montgomeryville, USA)[13]. Zeta potential was determined in HDL diluted 1:10 in KCl 10mM, using laser Doppler micro-electrophoresis, in the Zetasizer Nano ZS (Malvern Instruments, Malvern, UK). 2.7. Determination of proteins involved in HDL metabolism CETP and PLTP activities were measured using exogenous radiometric assays, as previously described[14, 15]. LPL and HL activities were measured in fasted post-heparin plasma samples, collected 15min after the intravenous administration of heparin (100U/kg body weight), in an assay based on fatty acid release from a radiolabeled triolein emulsion[16]. LCAT activity was determined using recombinant HDL, according to standardized method [17]. PON activity was measured using paraoxon (diethyl-p-nitrophenylphosphate, Sigma, St. Louis, MO, USA) as substrate [18]. 2.8. HDL antioxidant activity HDL antioxidant activity was measured in a kinetic fluorimetric assay adapted from Navab et al[19]. Oxidation was monitored as changes in the fluorescence intensity of 2',7'dichlorofluoresceine (DCFH). For the antioxidant activity assays, LDL (final concentration, 20mgTC/dL) and CuSO₄ (final concentration, 0.5μM) were added to DCFH-containing tubes (final concentration, 2mg/mL), followed by the addition or not of HDL (final concentration, 15mg total mass/dL). The volume was adjusted to 100μL with Chelex treated-PBS and the reaction mixture transferred onto a black 96-well microplate. The plate was covered with an optical adhesive cover to avoid evaporation and incubated at 37°C. Fluorescence intensity was measured over 24h with 15-minute intervals in a fluorescence microplate reader (Spectra Max M5; Molecular Devices, Sunnyvale, USA) at an excitation wavelength of 485nm, emission wavelength of 540 nm, and cut-off of 530nm. Results of antioxidant activity are presented as the percentage of inhibition of LDL oxidation in the presence of each subject's HDL when compared to control wells (LDL alone).

2.9. HDL anti-inflammatory activity

HDL's anti-inflammatory activity was measured in HUVEC in an assay adapted from Besler et al[20]. Cells were cultured in RPMI 1640 medium containing 10% fetal calf serum, penicillin, and streptomycin and maintained in a 5% CO₂ incubator at 37°C. After reaching confluence, they were plated in 24-well culture plate (3 x 10⁵ cells/well, and incubated with TNF-α (1ng/mL), with or without HDL (50μg ApoA-I/mL) for three hours. The culture media were collected and stored at -80°C. Due to the low VCAM-1 concentrations, samples were concentrated using the Amicon® Ultra Centrifugal Filters, 50K (Millipore, Massachusetts, USA) and then VCAM-1 concentrations were measured using the Human VCAM-1 ELISA Kit (Cat number ECM340, Millipore, Massachusetts, USA). Results are expressed as the percentage of decrease in VCAM-1 concentrations in the wells incubated with HDL when compared to the control wells without HDL.

2.10. Cholesterol efflux capacity (CEC) assay

Global cellular CEC was performed using J774 macrophages enriched with acetylated LDL and ¹⁴C-cholesterol and HDL as the cholesterol acceptor[21]. In summary, J774 macrophages were cultured in RPMI 1640 medium containing 10% fetal calf serum, penicillin, and streptomycin and maintained in a 5% CO₂ incubator at 37°C. After reaching confluence, cells were plated in a 96-well plate (1.25 x 10⁵ cells/well, and enriched with acetylated LDL (50

μg/mL) and 14 C-free cholesterol (0.3μCi / mL). After 48h, cells were washed with PBS containing fatty acid-free albumin (FAFA) and equilibrated with DMEM containing FAFA for 24 hours. The cells were then washed twice and incubated with HDL (50μg ApoA-I/mL) for 8 hours. Media were collected and the radioactivity measured in a beta-scintillation counter. Cells were rinsed twice with cold physiologic saline and the intracellular lipids extracted with hexane: isopropanol (3:2, v/v). Solvent was evaporated and radioactivity measured. The percentage of 14 C-CEC was calculated as (14 C-cholesterol in the medium/ 14 C-cholesterol in cells+medium) ×100.

2.11. HDL-mediated platelet aggregation inhibition

HDL ability to inhibit platelet aggregation was measured as described by Valiyaveettil et al[22]. HDL (0.8mg protein/mL) was mildly oxidized by dialysis against PBS + 5μ M CuSO₄, for 24h at 37°C. Citrated blood was drawn from a healthy donor and platelet-rich plasma (PRP) obtained by centrifugation at 800rpm for 15 minutes. PRP was then incubated with native or oxidized HDL (0.5 mg/mL) for 30 minutes at 37°C. Platelet aggregation was monitored using a Lumi-Aggregometer type 500 VS (Chrono-log, Havertown, USA) for 6 minutes after the addition of ADP (5μ M). Results are expressed as percentage of the inhibition of platelet aggregation induced by oxidized compared to native HDL.

2.12. Statistical analysis

The distribution of all variables was tested with Kolmogorov-Smirnov test. Jonckheere-Terpstra trend in one-tail test was used to evaluate demographic, clinical variables and HDL characterization among three groups clustered using BMI and expressed as median and interquartile range. ANCOVA was used to perform comparisons among groups involving enzymatic components of HDL adjusted for age, sex, and HOMA2 %S. Generalized linear models with type III sums of squares were used to assess interactions of BMI within the association between HDL functions and cIMT, the only outcome, adjusted for age, sex, HDL-C, BMI, and HOMA2 %S. HDL functions and HDL-C were modeled with generalized linear regression. The BMI effect on the cIMT among six HDL functions (HDL-C, HDL size, antioxidant activity, CEC, HDL-mediated platelet inhibition, and anti-inflammatory activity)

was evaluated with the use of interaction tests. We used complete case analysis to handle missing data. To construct the 3D surface plot 1, we included only HDL-C values between 40mg / dL and 100mg / dL; HDL size between 7.0 nm and 9.5 nm; CEC between 8% and 20%; antioxidant activity between 0 and 100%. For the remainder of the regression analyzes, we used the entire sample size of the sub-sample of 99 individuals. Two-sided p≤0.05 were considered to indicate statistical significance. Analyses were performed using IBM SPSS® version 21.0 statistical software. Scatter plot was performed using GraphPad Prism version 7.0 for Mac, GraphPad Software, La Jolla California USA, www.graphpad.com". Polinomial splines were used to evaluate the relation between BMI or carotid IMT vs CEC or Antioxidant activity or a compound variable, after transforming CEC and Antioxidant activity into positive z-scores. The compound variable (Z-Efflux + Z-Antioxidant activity) was defined by the sum of z-scores for CEC and antioxidant activity. In order to avoid overfitting, we excluded extreme values at xaxis (<5th percentile and >95% percentile) and smoothing parameters for polinomial derivation (degrees of freedom [df] and lambda) were defined after cross validation. Spline curves were performed in R software, version 3.2.1 (R Foundation for Statistical Computing). We used MATLAB® (version 4.10, The MathWorks, Inc, Apple Hill Drive Natick, MA) to fit a 3D curve using second polynomial least square surface.

3. Results

3.1. Overall study participants characteristics

The baseline characteristics of participants are shown in Table 1 stratified by BMI status (n=899). The female gender prevailed among the participants and BMI values were associated

with waist circumference, increased cIMT and impaired metabolic parameters; i.e. lower HDL-

C, Apo-AI and HOMA2%S, as well as higher triglycerides, insulin and fasting glucose.

Similarly, a stepped increase in LDL-C and total cholesterol was also noted with increasing

267 BMI.

242

243

244

245

246

247

248

249

250

251

252

253

254

255

256

257

258

259

260

261

264

265

266

268

3.2. Association between BMI, HDL-C and cIMT

270

271

272

273

274

275

276

277

278

279

280

281

282

283

284

285

286

287

288

289

290

291

292

293

294

295

In the whole studied sample (n=899), multivariable linear regression analyses adjusted for BMI, age, gender, and plasma insulin or HOMA2-IR, confirmed the association between cIMT and HDL-C (β=-0.11; 95%CI=-0.020;0.000; p=0.03) and identified the existence of a significant interaction of BMI upon this association (β =-1.80; p<0.0001). To visualize the pattern for such BMI interaction, 3D surface plots were applied based on second polynomial least square regression (Figure 1). As shown in the Figure 1A, in subjects with increased BMI, reduced HDL-C levels were associated with increased cIMT. In contrast, in those individuals with reduced BMI, no clear association was found between HDL-C and cIMT. In order to provide a deeper assessment of this interaction, a broad spectrum of HDL functions was investigated in a subgroup of these individuals. As it would be expected, an inverse association was found between BMI and HDL-C (Spearman's rho -0.028, p < 0.0001) and HDL size (Spearman's rho -0.175, p < 0.0001). 3.3. Association between BMI, HDL functions and cIMT in the subgroup analyses The subgroup characteristics are shown on Table 2. In the subgroup, we found a stepped decrease of total HDL mass, HDL size, and HDL content in triglyceride, free cholesterol, cholesteryl ester, and phospholipid across BMI categories (Table 3). PON activity adjusted for the total number of HDL particles, i.e. PON/HDL-C ratio, increased in parallel with BMI categories. There was no relation between BMI categories and activities of PLTP, LCAT, HL or LPL (Table 3). In line with previous studies, as shown in Figure 2A (linear beta -0.38, polynomial R2=0.19, p=0.001; Spearman's rho -0.32, p<0.001), we reported a progressive decline in CEC as BMI increases. In contrast, we found a progressive increase in HDL antioxidant activity which was proportional and reciprocal as compared with CEC (linear beta +1.38, polynomial R2=0.12, p=0.04) (Figure 2B). Both changes were mainly mediated by the HDL size which is inversely related to weight gain. Based on this assumption, the compound variable of ztransformed efflux plus antioxidant activity should remain approximately constant as HDL size changes due to excess weight (p value 0.75) (Figure 2C). Increasing values of the compound

297

298

299

300

301

302

303

304

305

306

307

308

309

310

311

312

313

314

315

316

317

318

319

320

321

322

323

variable were associated lower carotid IMT (linear beta -0.10, polynomial R2=0.26, p<0.001) (Figure 2D). Still, correlation analyses were made between BMI and HDL functions. An inverse association was also found with HDL-mediated platelet inhibition (Spearman's rho -0.157, p < 0.03). No correlation was found between BMI and HDL anti-inflammatory activity (Spearman's rho -0.009, p < 0.904) nor between each of the HDL functions. Since both the abundance of substrate, i.e. triglyceride-rich lipoproteins, and the activities of transport proteins are potentially involved in the effect of excess weight on HDL phenotype, multivariate linear regression models were applied to estimate the influence of intravascular HDL-remodeling proteins, i.e. CETP, LPL, HL, LCAT and PLTP on HDL size. CETP (β=-0.12; 95%CI=-0.30;-0.01; p=0.030), HL (β =-0.28; 95%CI=-0.35;-0.12; p<0.0001) and LCAT (β =-0.36; 95%CI=-0.28;-0.13; p<0.0001) were drivers for HDL size. HDL size was also associated with plasma triglycerides (β =-0.17; 95%CI=-0.06;-0.02; p<0.001), HOMA2-IR (β =0.21; 95%CI=0.01;0.42; p=0.001), PON activity/HDL-C (β=-0.33; 95%CI=-0.47;-0.13; p<0.0001) and HDL-mediated antioxidant activity (β=-0.70; 95%CI=-0.81;-0.12; p=0.009). Association was found between HOMA2-IR and HDL-mediated antioxidant activity (β=-2.1; 95%CI=-3.66;-0.60; p=0.007). In order to estimate the association between HDL functions and cIMT, we used multiple linear regression with adjustments for the following confounders (BMI, age, sex, HDL-c and insulin), which were selected based on univariate significance or clinical relevance (age, sex) (Table 4). We observed a negative association between CEC and cIMT, which remained significant after initial adjustment for the same confounders above, or even after adjustment for HDL size (β =-0.18; 95%CI=-0.138; -0.011; p=0.02), antioxidant activity (β =-0.19; 95%CI=-0.003;0.000; p=0.04) and PON activity/HDL-C (β =-0.16; 95%CI=-0.065;-0.002; p=0.02). The antioxidant activity of HDL was also inversely related to cIMT. Anti-inflammatory activity, PON activity/HDL-C and HDL-mediated platelet inhibition were not associated with cIMT in an adjusted model. Interactions of BMI were found within the linear associations between cIMT and CEC (p=0.03), and cIMT and antioxidant activity (p=0.04). Although the 95% CI suggests a tendency towards a moderating effect of the BMI on the association between HDL size and cIMT, this interaction did not reach statistical significance (p=0.13) (Fig. 1B). As displayed in Fig 1C, the inverse association between CEC and cIMT seems to increase in parallel with BMI values. In contrast, as shown in Fig 1D, the inverse association between cIMT and antioxidant activity of HDL increases with increasing BMI. In fact, the correlation between cIMT and antioxidant activity is greater in individuals with BMI above the median (23.6 kg/m2) (r=-0.33; p=0.037) than in their counterparts (r=-0.2; p=0.05) while the correlation between CEC and cIMT is equal in both subgroups (above, r=-0.28; p=0.042; below, r=-0.28; p=0.016).

4. Discussion

Recent data have shown that the predictive value of HDL-C for estimating the risk of cardiovascular events declines after CVD manifestation[23]; a failure that has been attributed to the increased generation of dysfunctional HDL in a setting of chronic or acute disease. As pointed out in subjects with CVD, we hypothesized that excess weight may influence the relationship between HDL-C and the risk of atherosclerotic disease. After confirming this hypothesis, we moved forward investigating whether more subtle changes in the HDL system could occur in overweight individuals and whether this could justify a change in the association pattern between HDL-C and atherosclerotic disease. Taken together, our findings revealed the following evidence: (i) the pattern of association between HDL-C and cIMT differs according to the presence or absence of excess weight; (ii) increased BMI is associated with the simultaneous change of multiple anti-atherosclerotic functions of HDL, including CEC and antioxidant activity; (iii) the existing association between excess weight and carotid atherosclerotic burden is in part attributable to HDL dysfunction; and (iv) HDL-mediated inhibition of platelet aggregation declines with excess weight.

To the best of our knowledge, only few studies have previously assessed the impact of body weight on HDL function in non-obese individuals and none used a simultaneous assessment of multiple functions. In this clinical setting, CEC has been the main HDL function

353

354

355

356

357

358

359

360

361

362

363

364

365

366

367

368

369

370

371

372

373

374

375

376

377

378

379

assessed, which was investigated in interventional [3], case-control[24] and cross-sectional [5] studies. In a large nested case-control study from the EPIC-Norfolk cohort, for example, discrete changes in BMI in the overweight range was inversely correlated with CEC [24]. On this specific aspect, our results are in line with previous studies. Weight gain promotes a wide range of metabolic changes, among which insulin resistance is the cornerstone for CVD risk. As a result of insulin resistance, for example, there is an increase in the fatty acid efflux and in the activities of CETP and HL leading to a reduction in HDL size, an increase in the ApoA-I catabolic rate and a reduction in CEC[5, 25, 26]. In contrast with the evidence in obese subjects [27-29], our study did not identify changes in CETP and HL activities across BMI categories although their activities were associated with HDL size change. Thus, at this stage of excess weight, the biochemical and size changes in HDL particles is more likely a consequence of increased substrate for HDL particle remodeling, i.e. increased plasma concentration of triglyceride-rich lipoproteins. These changes in the HDL system have traditionally been reported as a component cause for the increased risk of CVD in obese individuals [30]. In those who are overweight but below the obesity threshold, we revealed a similar scenario, i.e. insulin resistance inversely relates with overweight, HDL size and CEC. It is interesting to note that these changes occurred even before the threshold for overweight as defined by World Health Organization (WHO). Thus, according to previous translational studies[31] or actuarial analyzes based on observational cohorts[32], our data support the concept that the threshold for pathogenic body mass is probably below the WHO definition. Although it is clear that there is functional impairment, it is plausible that the change in the HDL phenotype would have an adaptive biological purpose motivated by the chronic increase of oxidative stress and by low-grade systemic inflammation. Similar reduction of HDL size has been reported in individuals who exhibit acute phase response, such as in myocardial infarction[33] and sepsis[34]. In these conditions, the reduction of HDL size is associated with a greater capacity to mitigate the oxidative stress. In agreement with this and consistent with previous studies, HDL size was inversely associated with increased antioxidant and PON

activities[35]. Interestingly, the predominance of small HDL (7.3-8.2 nm) in this cohort was associated with an attenuated impact of BMI on cIMT. Hence, overweight-induced remodeling in HDL simultaneously promoted the reduction of an anti-atherosclerotic mechanism, i.e. CEC, and the increase of another, i.e. antioxidant activity, suggesting a biological response of the HDL system to the predominant pro-atherosclerotic stimulus. Besides, the present study shows that estimates of the magnitude of HDL participation in the CVD risk in excess weight are naturally imprecise unless a broad range of anti-atherosclerotic functions is simultaneously investigated.

Obesity is clearly shown to be a prothrombotic state resulting from a combination of increased thrombin generation, platelet hyperactivity and decreased fibrinolysis[36]. Increased platelet reactivity is the result of the interaction between multiple characteristics grouped into obesity, including inflammation, oxidative stress, insulin resistance and adiposopathy with change in adipokine secretion pattern. Our study added to this state of knowledge, a new mechanism of imbalance in platelet activity; inhibition of HDL-mediated platelet aggregation was inversely associated with BMI. This finding should be considered in the set of prothrombotic changes of excess weight and as one of the mechanisms by which there is an increase in the incidence of cardiovascular events in these individuals.

Among the main limitations in the present study lies the fact that it is based on a cross-sectional design. In addition, due to the intensive laborious methodology involved in studying a full breadth of HDL function and metabolic pathways, we may have not been able to maintain the desired statistical power obtained as when the entire studied population was analyzed. In spite of this, it does provide us a unique opportunity to evaluate the association between excess weight and the HDL system early in the spectrum of metabolic derangement and atherogenesis. In fact, this may especially be true given the low rates of insulin resistance and more favorable lipid profile and systemic inflammatory activity of our study's participants.

In conclusion, our study indicates that higher BMI, even in non-obese, non-diabetic individuals, is associated with decreased function of several protective activities of HDL. In individuals with increased BMI, HDL dysfunction is directly associated with increased

- 408 atherosclerotic burden. Antioxidant activity is found to be an exception increasing with BMI
- and it partially attenuated the atherosclerotic burden.

411

412

413

414

415

416

417

418

419

420

421

422

423

424

425

426

427

428

429

430

Declaration of interest: The authors declare no conflict of interest. Funding The study was supported by São Paulo Research Foundation (FAPESP 2010/00201-8 and FAPESP 2006/60585-9 and CNPq (471380/2008-13). JCLJ was supported by a doctoral grant from Coordination for the Improvement of Higher-Level Education Personnel (Capes grant number PROEX0092045). NBP was supported by a doctoral grant (number 2012/01645-2) from the Foundation for Research Support of the State of Sao Paulo (FAPESP). Prof Sposito was supported by a fellowship grant of productivity in research from the National Council for Scientific and Technological Development (CNPq) (grant number 301465/2017-7). Author contribution statement: Jose Carlos de Lima-Junior drafted the manuscript and participated on the analysis of the data, Vitor W.M. Virginio participated on the experiments, Filipe A. Moura participated on the drafting of the manuscript and analysis of the data, Adriana Bertolami participated on the experiments, Marcelo Bertolami participated critically reviewing the manuscript, Wilson Nadruz participated critically reviewing the manuscript, Eliana Cota de Faria participated on the experiments and analysis of the data, Ilaria Zanotti participated critically reviewing the manuscript, Luiz Sergio F. de Carvalho participated on the analysis of the data and critically reviewing the manuscript, Andrei C Sposito participated on the analysis of the data and critically reviewing the manuscript Acknowledgements. We thank Natalia B. Panzoldo from the University of Campinas for technical assistance in HDL functions experiments.

5. References

- 432 [1] D.K. Tobias, A. Pan, C.L. Jackson, E.J. O'Reilly, E.L. Ding, W.C. Willett, J.E. Manson, F.B. Hu,
- 433 Body-mass index and mortality among adults with incident type 2 diabetes, N Engl J Med
- 434 370(3) (2014) 233-44.

- 435 [2] A. Afshin, M.H. Forouzanfar, M.B. Reitsma, P. Sur, K. Estep, A. Lee, L. Marczak, A.H.
- 436 Mokdad, M. Moradi-Lakeh, M. Naghavi, J.S. Salama, T. Vos, K.H. Abate, C. Abbafati, M.B.
- 437 Ahmed, Z. Al-Aly, A. Alkerwi, R. Al-Raddadi, A.T. Amare, A. Amberbir, A.K. Amegah, E. Amini,
- 438 S.M. Amrock, R.M. Anjana, J. Ärnlöv, H. Asayesh, A. Banerjee, A. Barac, E. Baye, D.A. Bennett,
- 439 A.S. Beyene, S. Biadgilign, S. Biryukov, E. Bjertness, D.J. Boneya, I. Campos-Nonato, J.J. Carrero,
- 440 P. Cecilio, K. Cercy, L.G. Ciobanu, L. Cornaby, S.A. Damtew, L. Dandona, R. Dandona, S.D.
- Dharmaratne, B.B. Duncan, B. Eshrati, A. Esteghamati, V.L. Feigin, J.C. Fernandes, T. Fürst, T.T.
- 442 Gebrehiwot, A. Gold, P.N. Gona, A. Goto, T.D. Habtewold, K.T. Hadush, N. Hafezi-Nejad, S.I.
- 443 Hay, M. Horino, F. Islami, R. Kamal, A. Kasaeian, S.V. Katikireddi, A.P. Kengne, C.N.
- Kesavachandran, Y.S. Khader, Y.H. Khang, J. Khubchandani, D. Kim, Y.J. Kim, Y. Kinfu, S. Kosen,
- T. Ku, B.K. Defo, G.A. Kumar, H.J. Larson, M. Leinsalu, X. Liang, S.S. Lim, P. Liu, A.D. Lopez, R.
- Lozano, A. Majeed, R. Malekzadeh, D.C. Malta, M. Mazidi, C. McAlinden, S.T. McGarvey, D.T.
- Mengistu, G.A. Mensah, G.B.M. Mensink, H.B. Mezgebe, E.M. Mirrakhimov, U.O. Mueller, J.J.
- 448 Noubiap, C.M. Obermeyer, F.A. Ogbo, M.O. Owolabi, G.C. Patton, F. Pourmalek, M. Qorbani, A.
- 449 Rafay, R.K. Rai, C.L. Ranabhat, N. Reinig, S. Safiri, J.A. Salomon, J.R. Sanabria, I.S. Santos, B.
- 450 Sartorius, M. Sawhney, J. Schmidhuber, A.E. Schutte, M.I. Schmidt, S.G. Sepanlou, M.
- 451 Shamsizadeh, S. Sheikhbahaei, M.J. Shin, R. Shiri, I. Shiue, H.S. Roba, D.A.S. Silva, J.I. Silverberg,
- 452 J.A. Singh, S. Stranges, S. Swaminathan, R. Tabarés-Seisdedos, F. Tadese, B.A. Tedla, B.S.
- Tegegne, A.S. Terkawi, J.S. Thakur, M. Tonelli, R. Topor-Madry, S. Tyrovolas, K.N. Ukwaja, O.A.
- 454 Uthman, M. Vaezghasemi, T. Vasankari, V.V. Vlassov, S.E. Vollset, E. Weiderpass, A.
- 455 Werdecker, J. Wesana, R. Westerman, Y. Yano, N. Yonemoto, G. Yonga, Z. Zaidi, Z.M. Zenebe,
- 456 B. Zipkin, C.J.L. Murray, G.O. Collaborators, Health Effects of Overweight and Obesity in 195
- 457 Countries over 25 Years, N Engl J Med 377(1) (2017) 13-27.
- 458 [3] A.A. Khan, P.A. Mundra, N.E. Straznicky, P.J. Nestel, G. Wong, R. Tan, K. Huynh, T.W. Ng,
- 459 N.A. Mellett, J.M. Weir, C.K. Barlow, Z.H. Alshehry, G.W. Lambert, B.A. Kingwell, P.J. Meikle,
- Weight Loss and Exercise Alter the High-Density Lipoprotein Lipidome and Improve High-
- Density Lipoprotein Functionality in Metabolic Syndrome, Arterioscler Thromb Vasc Biol 38(2)
- 462 (2018) 438-447.
- 463 [4] F.M. Sacks, M.K. Jensen, From High-Density Lipoprotein Cholesterol to Measurements of
- 464 Function: Prospects for the Development of Tests for High-Density Lipoprotein Functionality in
- 465 Cardiovascular Disease, Arterioscler Thromb Vasc Biol 38(3) (2018) 487-499.
- 466 [5] T. Sasahara, P. Nestel, N. Fidge, D. Sviridov, Cholesterol transport between cells and high
- density lipoprotein subfractions from obese and lean subjects, J Lipid Res 39(3) (1998) 544-54.
- 468 [6] N. Attia, N. Fournier, B. Vedie, M. Cambillau, P. Beaune, O. Ziegler, A. Grynberg, J.L. Paul, B.
- 469 Guerci, Impact of android overweight or obesity and insulin resistance on basal and
- 470 postprandial SR-BI and ABCA1-mediated serum cholesterol efflux capacities, Atherosclerosis
- 471 209(2) (2010) 422-9.
- 472 [7] A.C. Sposito, HDL metrics, let's call the number thing off?, Atherosclerosis 251 (2016) 525-
- 473 527.
- 474 [8] J.C. Levy, D.R. Matthews, M.P. Hermans, Correct homeostasis model assessment (HOMA)
- evaluation uses the computer program, Diabetes Care 21(12) (1998) 2191-2.
- 476 [9] A. Bertolami, J.C. de Lima-Júnior, R.M. Cintra, L.S. Carvalho, C.C. Gonzaga, M.L. Sulzbach,
- 477 A.C.G.P. Petisco, J.E.M. Barbosa, A.A. Faludi, J. Plutzky, M.C. Bertolami, A.C. Sposito,
- 478 Adiponectin concentration data improve the estimation of atherosclerotic risk in normal and in
- overweight subjects, Clin Endocrinol (Oxf) (2017).

- 480 [10] J.H. Stein, C.E. Korcarz, R.T. Hurst, E. Lonn, C.B. Kendall, E.R. Mohler, S.S. Najjar, C.M.
- 481 Rembold, W.S. Post, F. American Society of Echocardiography Carotid Intima-Media Thickness
- 482 Task, Use of carotid ultrasound to identify subclinical vascular disease and evaluate
- 483 cardiovascular disease risk: a consensus statement from the American Society of
- 484 Echocardiography Carotid Intima-Media Thickness Task Force. Endorsed by the Society for
- 485 Vascular Medicine, Journal of the American Society of Echocardiography: official publication
- of the American Society of Echocardiography 21(2) (2008) 93-111; quiz 189-90.
- 487 [11] M.W. Lorenz, S. von Kegler, H. Steinmetz, H.S. Markus, M. Sitzer, Carotid intima-media
- 488 thickening indicates a higher vascular risk across a wide age range: prospective data from the
- 489 Carotid Atherosclerosis Progression Study (CAPS), Stroke 37(1) (2006) 87-92.
- 490 [12] M.J. Chapman, S. Goldstein, D. Lagrange, P.M. Laplaud, A density gradient ultracentrifugal
- procedure for the isolation of the major lipoprotein classes from human serum, J Lipid Res
- 492 22(2) (1981) 339-58.
- 493 [13] E.S. Lima, R.C. Maranhao, Rapid, simple laser-light-scattering method for HDL particle
- 494 sizing in whole plasma, Clin Chem 50(6) (2004) 1086-8.
- 495 [14] L. Lagrost, Determination of the mass concentration and the activity of the plasma
- 496 cholesteryl ester transfer protein (CETP), Methods Mol Biol 110 (1998) 231-41.
- 497 [15] M. Jauhiainen, C. Ehnholm, Determination of human plasma phospholipid transfer protein
- 498 mass and activity, Methods 36(2) (2005) 97-101.
- 499 [16] C. Ehnholm, T. Kuusi, Preparation, characterization, and measurement of hepatic lipase,
- 500 Methods Enzymol 129 (1986) 716-38.
- 501 [17] J.W. Chisholm, A.K. Gebre, J.S. Parks, Characterization of C-terminal histidine-tagged
- 502 human recombinant lecithin: cholesterol acyltransferase, J Lipid Res 40(8) (1999) 1512-9.
- 503 [18] D.Z. Scherrer, V.H. Zago, I.C. Vieira, E.S. Parra, N.B. Panzoldo, F. Alexandre, R. Secolin, J.
- Baracat, E.C. Quintão, E.C. Faria, p.Q192R SNP of PON1 seems not to be Associated with
- 505 Carotid Atherosclerosis Risk Factors in an Asymptomatic and Normolipidemic Brazilian
- 506 Population Sample, Arg Bras Cardiol 105(1) (2015) 45-52.
- 507 [19] M. Navab, S.Y. Hama, G.P. Hough, G. Subbanagounder, S.T. Reddy, A.M. Fogelman, A cell-
- free assay for detecting HDL that is dysfunctional in preventing the formation of or inactivating
- oxidized phospholipids, J Lipid Res 42(8) (2001) 1308-17.
- 510 [20] C. Besler, K. Heinrich, L. Rohrer, C. Doerries, M. Riwanto, D.M. Shih, A. Chroni, K.
- 511 Yonekawa, S. Stein, N. Schaefer, M. Mueller, A. Akhmedov, G. Daniil, C. Manes, C. Templin, C.
- 512 Wyss, W. Maier, F.C. Tanner, C.M. Matter, R. Corti, C. Furlong, A.J. Lusis, A. von Eckardstein,
- 513 A.M. Fogelman, T.F. Luscher, U. Landmesser, Mechanisms underlying adverse effects of HDL
- on eNOS-activating pathways in patients with coronary artery disease, J Clin Invest 121(7)
- 515 (2011) 2693-708.
- 516 [21] A. Machado-Lima, R.T. Iborra, R.S. Pinto, C.H. Sartori, E.R. Oliveira, E.R. Nakandakare, J.T.
- 517 Stefano, D. Giannella-Neto, M.L. Correa-Giannella, M. Passarelli, Advanced glycated albumin
- 518 isolated from poorly controlled type 1 diabetes mellitus patients alters macrophage gene
- 519 expression impairing ABCA-1-mediated reverse cholesterol transport, Diabetes Metab Res Rev
- 520 29(1) (2013) 66-76.
- 521 [22] M. Valiyaveettil, N. Kar, M.Z. Ashraf, T.V. Byzova, M. Febbraio, E.A. Podrez, Oxidized high-
- density lipoprotein inhibits platelet activation and aggregation via scavenger receptor BI, Blood
- 523 111(4) (2008) 1962-71.
- 524 [23] G. Silbernagel, B. Schottker, S. Appelbaum, H. Scharnagl, M.E. Kleber, T.B. Grammer, A.
- Ritsch, U. Mons, B. Holleczek, G. Goliasch, A. Niessner, B.O. Boehm, R.B. Schnabel, H. Brenner,
- 526 S. Blankenberg, U. Landmesser, W. Marz, High-density lipoprotein cholesterol, coronary artery
- disease, and cardiovascular mortality, Eur Heart J 34(46) (2013) 3563-71.
- 528 [24] D. Saleheen, R. Scott, S. Javad, W. Zhao, A. Rodrigues, A. Picataggi, D. Lukmanova, M.L.
- Mucksavage, R. Luben, J. Billheimer, J.J. Kastelein, S.M. Boekholdt, K.T. Khaw, N. Wareham,
- 530 D.J. Rader, Association of HDL cholesterol efflux capacity with incident coronary heart disease
- events: a prospective case-control study, Lancet Diabetes Endocrinol 3(7) (2015) 507-13.

- 532 [25] E.S. Parra, N.B. Panzoldo, V.H. Zago, D.Z. Scherrer, F. Alexandre, J. Bakkarat, V.S. Nunes,
- 533 E.R. Nakandakare, E.C. Quintao, W. Nadruz, Jr., E.C. de Faria, A.C. Sposito, HDL size is more
- accurate than HDL cholesterol to predict carotid subclinical atherosclerosis in individuals
- classified as low cardiovascular risk, PLoS One 9(12) (2014) e114212.
- 536 [26] M. de la Llera Moya, F.C. McGillicuddy, C.C. Hinkle, M. Byrne, M.R. Joshi, V. Nguyen, J.
- Tabita-Martinez, M.L. Wolfe, K. Badellino, L. Pruscino, N.N. Mehta, B.F. Asztalos, M.P. Reilly,
- Inflammation modulates human HDL composition and function in vivo, Atherosclerosis 222(2)
- 539 (2012) 390-4.
- [27] T. Arai, S. Yamashita, K. Hirano, N. Sakai, K. Kotani, S. Fujioka, S. Nozaki, Y. Keno, M.
- 541 Yamane, E. Shinohara, Increased plasma cholesteryl ester transfer protein in obese subjects. A
- 542 possible mechanism for the reduction of serum HDL cholesterol levels in obesity, Arterioscler
- 543 Thromb 14(7) (1994) 1129-36.
- [28] C.F. Ebenbichler, M. Laimer, S. Kaser, A. Ritsch, A. Sandhofer, H. Weiss, F. Aigner, J.R.
- Patsch, Relationship between cholesteryl ester transfer protein and atherogenic lipoprotein
- profile in morbidly obese women, Arterioscler Thromb Vasc Biol 22(9) (2002) 1465-9.
- 547 [29] C.P.J. Talbot, J. Plat, P.J. Joris, M. Konings, Y.H.A.M. Kusters, C.G. Schalkwijk, A. Ritsch, R.P.
- Mensink, HDL cholesterol efflux capacity and cholesteryl ester transfer are associated with
- body mass, but are not changed by diet-induced weight loss: A randomized trial in abdominally
- obese men, Atherosclerosis 274 (2018) 23-28.
- [30] B. Shao, C. Tang, A. Sinha, P.S. Mayer, G.D. Davenport, N. Brot, M.N. Oda, X.Q. Zhao, J.W.
- Heinecke, Humans with atherosclerosis have impaired ABCA1 cholesterol efflux and enhanced
- 553 high-density lipoprotein oxidation by myeloperoxidase, Circ Res 114(11) (2014) 1733-42.
- [31] L.H. Bogl, S.M. Kaye, J.T. Ramo, A.J. Kangas, P. Soininen, A. Hakkarainen, J. Lundbom, N.
- Lundbom, A. Ortega-Alonso, A. Rissanen, M. Ala-Korpela, J. Kaprio, K.H. Pietilainen, Abdominal
- obesity and circulating metabolites: A twin study approach, Metabolism 65(3) (2016) 111-21.
- 557 [32] K. Bhaskaran, I. Dos-Santos-Silva, D.A. Leon, I.J. Douglas, L. Smeeth, Association of BMI
- 558 with overall and cause-specific mortality: a population-based cohort study of 3.6 million adults
- in the UK, Lancet Diabetes Endocrinol (2018).
- 560 [33] L.S. Carvalho, V.W. Virginio, N.B. Panzoldo, V.N. Figueiredo, S.N. Santos, R.G. Modolo, J.M.
- Andrade, E.S.J.C. Quinaglia, W. Nadruz-Junior, E.C. de Faria, A.C. Sposito, G. Brasilia Heart
- 562 Study, Elevated CETP activity during acute phase of myocardial infarction is independently
- associated with endothelial dysfunction and adverse clinical outcome, Atherosclerosis 237(2)
- 564 (2014) 777-83.
- 565 [34] A. Pirillo, A.L. Catapano, G.D. Norata, HDL in infectious diseases and sepsis, Handb Exp
- 566 Pharmacol 224 (2015) 483-508.
- 567 [35] A. Kontush, S. Chantepie, M.J. Chapman, Small, dense HDL particles exert potent
- protection of atherogenic LDL against oxidative stress, Arterioscler Thromb Vasc Biol 23(10)
- 569 (2003) 1881-8

- 570 [36] F. Santilli, N. Vazzana, R. Liani, M.T. Guagnano, G. Davi, Platelet activation in obesity and
- 571 metabolic syndrome, Obes Rev 13(1) (2012) 27-42.

Figure 1. 3D surface plot showing the association between BMI, cIMT, and HDL variables. This surface plot displays an image based on the relationship between the BMI and HDL variables as predictors on the x- and y-axes and a continuous surface that represents the cIMT values on the z-axis. The peak on the plot corresponds with the yellow color and the highest value obtained to cIMT using the combination of X and Y that produce the maxima cIMT, which occurs at approximately 0.8mm. The valley corresponds with blue color and the combination of X and Y that produce the minima cIMT. Figure 1A, HDL-C values. Figure 1B, HDL size. Figure 1C, CEC values. Figure 1D, antioxidant activity of HDL. HDL-C, highdensity lipoprotein cholesterol in mg/dL. BMI, body mass index in kg/m². CEC is expressed as a percentage of efflux in the sample, normalized to a reference sample. Antioxidant activity is expressed in % as inhibition of LDL oxidation in the presence of each subject's HDL oxidation. Figure 2. Polynomial splines showing the associations between BMI, cIMT and HDL variables, 2A, CEC according to BMI values. 2B, Antioxidant activity according to BMI values. 2C, compound variable (Z-Efflux + Z-Antioxidant activity) according to BMI values. 2D, cIMT values according to compound variable (Z-Efflux + Z-Antioxidant activity). Gray shading indicates 95% confidence intervals.

Table 1. Clinical characteristics according to BMI groups

BMI categories (kg/m2)

	<22	22-24.99	25-30	p-value
Sample size	186	264	449	
BMI, kg/m ²	20.6 (1.8)	23.6 (1.6) ^a	28 (4.6) ^{b,c}	< 0.0001
Waist circumference, cm	68 (9)	75 (11) ^a	94 (19) ^{b,c}	< 0.0001
Age, yr	38 (24)	45.5 (26) ^a	54 (16) ^b	0.003
Male sex, %	43.5	44.7	39.6	0.369
Hypertension, %	28.6	31.3	28.3	0.915
Glucose, mg/dL	81 (12.0)	86 (14.0) ^a	105 (62.0) ^{b,}	<0.0001
Insulin, μU/mL	3.0 (2.5)	4.7 (4.9) ^a	10.2 (8.2) ^{b,c}	< 0.0001
НОМА2 % β	61.9 (38.2)	61.3 (49.4)	64.9 (51.3) ^b	0.008
HOMA2 %S	241.7 (210.3)	161.2 (183.5)	68.8 (62.5) ^b	<0.0001
HOMA2-IR	0.46 (0.4)	0.51 (0.5)	$0.66 (0.5)^{b,c}$	< 0.0001
CRP, mg/dL	0.42 (0.9)	0.70 (1.1)	0.51 (1.0)	0.453
Triglycerides, mg/dL	66 (34)	81 (46) ^a	118 (87) ^{b,c}	<0.0001
LDL-C, mg/dL	95 (40)	104 (34) ^a	107 (42) ^b	< 0.0001
Total cholesterol, mg/dL	175 (53)	181 (50)	187 (55) ^{b,c}	< 0.0001
ApoA-I, mg/dL	148 (53)	142 (46)	137 (38) ^{b,c}	< 0.0001
ApoB, mg/dL	72 (23)	81 (27) ^a	90 (31) ^b	<0.0001
HDL-C, mg/dL	63 (29)	52 (30) ^a	45 (19) ^{b,c}	< 0.0001

 $0.70(0.24)^{b,c}$ 0.55 (0.20) $0.60(0.20)^{a}$ < 0.0001 cIMT, mm All continuous variables are expressed as medians and interquartile ranges, and categorical variables as percentages. Comparisons between groups were analyzed with Jonckheere-Terpstra's for ordered alternatives with pairwise comparisons, or Chi-Square test for the categorical variables. To convert the values for glucose to millimoles per liter, divide by 18. To convert the values for insulin to picomoles per liter, multiply by 6.945. To convert the values for cholesterol to millimoles per liter, multiply by 0.02586. To convert the values for triglycerides to millimoles per liter, multiply by 0.01129. ^aBMI 22 – 24.9 vs BMI <22; ^bBMI >25 vs 22 - 24.9; ^cBMI > 25 vs BMI < 22. Significant p-value < 0.05.

 Table 2. Subgroup clinical characteristics according to BMI groups

	BMI categories (kg/m2)							
	<22		22-24.99		25-30		p-value	
Sample size	34		47		20			
BMI, kg/m ²		20.0	(2.5)	23.5 (1.6	() ^a	26.7	(2.55) ^{b,c}	<0.0001
Waist circumference, c	m	65.0	(7.0)	75.5 (13.	.2) ^a	84.0 ($(10.5)^{b,c}$	<0.0001
Age, yr		42 (2	21)	39 (20.7))	47 (9.	.5)	0.24
Male sex, %		33.7		46.5		19.8		0.47
Glucose, mg/dL		80.0	(8.0)	83.0 (9.2	2)	86.0 ((11.5) ^b	0.012
Insulin, μU/mL		2.5 (2	2.0)	4.3 (4.0)	a	5.8 (6	(i.0) ^{b,c}	<0.0001
HOMA2 % β		58.4	(37.8)	69.0 (45.	9)	84.9 ((38.7) ^b	<0.0001
HOMA2 %S		303.2	2 (261.6)	228.2 (22	21.9) ^a	148.2	$(75.1)^{b,c}$	<0.0001
HOMA2-IR		0.3 (0.3)	0.4 (0.5)	a	0.7 (0	0.5) ^{b,c}	< 0.0001
CRP, mg/dL		0.9 (1.5)	0.71 (1.2	2)	0.6 (1	.2)	0.51
Triglycerides, mg/dL		57.0	(27.2)	70.0 (29.	0)	123.5	$(72.7)^{b,c}$	< 0.0001
LDL-C, mg/dL		98.0	(30.5)	100.0 (34	4.0)	101.0	(28.5)	0.57
Total cholesterol, mg/d	L	181.0	(48.7)	169.0 (42	2.0)	173.0	(34.5)	0.13
ApoA-I, mg/dL		176.0	0 (61.2)	147.0 (53	3.0)	111.0	$(57.2)^{b,c}$	< 0.0001
ApoB, mg/dL		73.7	(24.3)	81.3 (26.	.1)	81.7 ((22.3) ^b	0.04
HDL-C, mg/dL		72.5	(39.0)	49.0 (52.	.0) ^a	32.5 ($(15.0)^{b,c}$	< 0.0001
cIMT, mm		0.55	(0.2)	0.58 (0.2		0.67	(0.5)	0.05

All continuous variables are expressed as medians and interquartile ranges, and categorical variables as percentages. Comparisons between groups were analyzed with Jonckheere-Terpstra's for ordered alternatives with pairwise comparisons, or Chi-Square test for the categorical variables. To convert the values for glucose to millimoles per liter, divide by 18. To convert the values for insulin to picomoles per liter, multiply by 6.945. To convert the values for cholesterol to millimoles per liter, multiply by 0.02586. To convert the values for triglycerides to millimoles per liter, multiply by 0.01129. ^aBMI 22 – 24.9 vs BMI <22; ^bBMI >25 vs 22 - 24.9; ^cBMI > 25 vs BMI < 22. Significant p-value < 0.05.

Table 3. HDL characterization

	BMI categories (kg/m2)				
	<22	22-24.99	25-30	p-value	
Sample size	34	47	20		
Total mass, mg/dL	198.8 (91)	182.3 (98)	155 (99) ^c	0.024	
Triglycerides, mg/dL	9.8 (6.0)	7.8 (4.0)	8.3 (6)	0.047	
Free cholesterol, mg/dL	8.0 (6.0)	6.3 (4.0) ^a	5.3 (3.0) ^c	0.001	
Cholesteryl ester, mg/dL	60.1 (35)	52.9 (46)	39.7 (26) ^c	0.004	
Phospholipids, mg/dL	35.1 (19)	29.2 (14) ^a	24.7 (13)°	<0.0001	
ApoA-I, mg/dL	86.1 (40)	86.1 (48)	76.9 (39)	0.578	
Total proteins, mg/dL	135.5 (71.5)	143.6 (74)	147.0 (54.0)	0.777	
HDL size, nm	7.9 (0.9)	7.8 (0.9)	7.6 (0.8) ^{b,c}	<0.0001	
Zeta potential, mV	-7.7 (5)	-6.4 (4)	-7.8 (9)	0.297	
CETP, %	10.1 (6.4)	10.6 (7.3)	10.7 (6.3)	0.612	
PLTP, μmol PC/mL/h	5.7 (2.9)	6.0 (3.2)	5.4 (3.5)	0.338	
LCAT, nmol CE/mL/h	17.4 (15)	16.6 (12)	16.9 (19)	0.454	
LPL, µmol FFA/mL/h	4.0 (3.4)	3.7 (3.7)	3.2 (2.9)	0.157	
HL, μmol FFA/mL/h	4.9 (4.0)	5.8 (4.4)	5.8 (4.5)	0.440	
PON/HDL-C, (mmol/min)/(mg/dL)	0.40 (0.5)	0.50 (0.7) ^a	0.54 (0.7)°	<0.001	

All continuous variables are expressed as medians and interquartile ranges. To convert values for cholesterol to millimoles per liter, multiply by 0.02586. To convert values for triglycerides to millimoles per liter, multiply by 0.01129. ^aBMI 22 - 24.9 vs BMI <22; ^bBMI >25 vs 22 -24.9; ^cBMI > 25 vs BMI < 22. Significant p-value < 0.05.

Table 4. Linear regression analyses between HDL functions and cIMT

Independent variable	Unstandardized β	Standardized β	Lower CI 95%	Upper CI 95%	<i>p</i> -value
Antioxidant activity					
Unadjusted Adjusted ^a	-0.001	-0.153	-0.003	0.000	0.128
Adjusted	-0.001	-0.196	-0.003	0.000	0.128
CEC	******	0.12, 0	0.000		0.000
Unadjusted	-0.016	-0.260	-0.028	-0.004	0.009
Adjusted ^a	-0.012	-0.188	-0.023	0.000	0.047
PON/HDL-C					
Unadjusted	-0.010	-0.063	-0.079	0.024	0.301
Adjusted ^a	-0.045	-0.061	-0.071	0.019	0.254
Anti-inflammatory activity					
Unadjusted	0.000	-0.043	-0.003	0.002	0.676
Adjusted ^a	0.000	-0.004	-0.002	0.002	0.963
HDL-mediated platelet inhibition					
Unadjusted	0.002	0.164	0.000	0.004	0.120
Adjusted ^a	0.002	0.177	0.000	0.004	0.068

 $^{^{\}rm b}$ Adjusted for age, sex, BMI, HDL-C and insulin. In order to compare effects across different HDL functions we provided the standardized coefficients.



